Want more about Corporate Strategy to land in your mailbox?

Omnicare, Teva unit pay $112 million for kickbacks
WASHINGTON (Reuters) - Omnicare Inc, the largest U.S. provider of pharmacy services to nursing homes, will pay $98 million and Teva subsidiary IVAX Pharmaceuticals will pay $14 million to settle allegations of kickbacks, the U.S. Department of Justice said on Tuesday.
The department said Omnicare both solicited and paid kickbacks.
Omnicare allegedly asked IVAX to pay $8 million in exchange for agreeing to purchase $50 million in IVAX drugs, the DOJ said.
It also accused Omnicare of soliciting kickbacks from Johnson & Johnson <JNJ.N> in exchange for recommending that physicians prescribe the antipsychotic drug Risperdal to nursing home patients.
"J&J's kickbacks to Omnicare took multiple forms, including rebates that were conditioned on Omnicare engaging in an 'Active Intervention Program' for Risperdal and payments disguised as data purchase fees, educational grants, and fees to attend Omnicare meetings," the Justice Department said.
Omnicare said it settled the allegations without admitting any wrongdoing.
"The settlement agreement does not include any finding of wrongdoing or any admission of liability by Omnicare," the company said in a statement. "The company denies the contentions of the federal government and the qui tam relators (whistle-blowers) as set forth in the complaints and further denies any liability related to those contentions."
Teva said in an email statement that "IVAX denies any liability relating to the contract at issue," adding that it was executed "years before IVAX was acquired by Teva."
Teva said it settled "to avoid the uncertainty and expense of litigation."
(Reporting by Diane Bartz; Editing by Maureen Bavdek, Gary Hill)


Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
Harsh Manglik
Chairman
Accenture India
Accenture India to hire aggressively for select verticals
Vishal Doshi
Managing Director
Shrenju & Company
Shrenuj & Company will project 15% rev rise this yr
MP Taparia
Chairman
Supreme Petrochemicals
Supreme Petrochemicals expects Rs 2200cr rev in next 1.5yrs
Vineet Nayyar
Chief Executive Officer
HCL Technologies
HCL Tech plans to merge arms with itself, eyes new spots
-
Most Read
-
Most Viewed
- UBS Sec: Good level to enter mkts, suggests stocks

- Mitesh Thacker's top 5 picks for today's trade

- Nifty to cross 5100; infra, banking best bets: Quantum Sec

- End of BPLR: RBI to de-regulate lending rates in FY11

- ARSS Infrastructure IPO opens; should you subscribe?
- Jubilant Food's anchor investors buy add'l stake on debut
- SAIL to issue bonus shares before FPO: Sources

- Ten success stories in unheard of sectors
- What is Religare Capital betting on in the long-term?

- India a stock picker's market: JPMorgan Sec

- China confirmed as global export champion
Source: ft.com
- Time to understand how the mighty fall
Source: ft.com
- India growth set to near 2007 boom levels
Source: ft.com
- Speculators build record bets against euro
Source: ft.com














